Business, energy, technology, markets and global industry news from Business News Today

United States Drug Enforcement Administration

PharmaDeviceNews United States Drug Enforcement Administration
Otsuka’s FDA approval of SIMTRIYO, or centanafadine, introduces a first-in-class ADHD treatment for adults and children aged six and older, although DEA scheduling, safety monitoring and payer access will shape its commercial adoption. Representative image.
Pharma & Biotech

Otsuka’s SIMTRIYO has FDA approval, but two hurdles will decide whether it can disrupt ADHD care

Otsuka’s SIMTRIYO wins FDA approval for ADHD, but DEA scheduling, boxed warnings and payer access will shape its commercial uptake.

Read More